Send to

Choose Destination
Biomark Insights. 2012;7:71-9. doi: 10.4137/BMI.S9873. Epub 2012 Jun 25.

Characterization of Antibodies that Detect Human GFAP after Traumatic Brain Injury.

Author information

Banyan Biomarkers Inc., Alachua, Florida, USA.


After traumatic brain injury (TBI), glial fibrillary acidic protein (GFAP) and other brain-derived proteins and their breakdown products are released into biofluids such as CSF and blood. Recently, a sandwich ELISA was constructed that measured GFAP concentrations in CSF or serum from human mild-moderate TBI patients. The goals of the present study were to characterize the same two antibodies used in this ELISA, and to determine which GFAP bands are detected by this antibody combination. Here, both antibodies recognized GFAP specifically in human brain and post-TBI CSF in a cluster of bands ranging from 50-38 kDa, that resembled bands from calpain-cleaved GFAP. By immunoprecipitation, the anti-GFAP Capture antibody recovered full length GFAP and its breakdown products from human brain lysate and post-TBI CSF. These findings demonstrate that the anti-GFAP ELISA antibodies non-preferentially detect intact GFAP and GFAP breakdown products, underscoring their utility for detecting brain injury in human patients.


GFAP; GFAP-BDP; human; traumatic brain injury

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center